Real-World study tracks MS Patients' persistence on ozanimod
NCT ID NCT05811416
First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 26 times
Summary
This study follows 200 adults with relapsing-remitting multiple sclerosis (RRMS) who are starting the drug ozanimod for the first time. Researchers want to see how long patients continue taking the medication and how well it works in everyday medical practice. The study does not test a new treatment but collects real-world data to help doctors understand patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Barcelona, 08008, Spain
Conditions
Explore the condition pages connected to this study.